[1]殷蓓丽,蔡奚梅,钱云英,等.修和方加减联合化疗治疗卵巢癌手术切除后临床观察[J].陕西中医,2025,46(5):634-637.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.012]
　YIN Beili,CAI Ximei,QIAN Yunying,et al.The effects of modified Xiuhe prescription combined with paclitaxel and platinum on the patients with surgically resected ovarian cancer[J].,2025,46(5):634-637.[doi:DOI:10.3969/j.issn.1000-7369.2025.05.012]
点击复制

修和方加减联合化疗治疗卵巢癌手术切除后临床观察
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年5期
页码:
634-637
栏目:
临床研究
出版日期:
2025-05-05

文章信息/Info

Title:
The effects of modified Xiuhe prescription combined with paclitaxel and platinum on the patients with surgically resected ovarian cancer
作者:
殷蓓丽; 蔡奚梅; 钱云英; 须慕棠
(常熟市中医院妇产科,江苏 常熟 215500)
Author(s):
YIN Beili; CAI Ximei; QIAN Yunying; XU Mutang
(Department of Obstetrics and Gynecology,Changshu Traditional Chinese Medicine Hospital,Changshu 215500,China)
关键词:
卵巢癌;  气血两虚证;  修和方加减;  PTX;  铂类;  预后;  中医证候;  免疫功能
Keywords:
Ovarian cancer;  Qi and blood deficiency syndrome;  Modified Xiuhe Prescription;  PTX;  Platinum;  Prognosis;  Traditional Chinese Medicine Syndrome;  Immunity
分类号:
R 737.31
DOI:
DOI:10.3969/j.issn.1000-7369.2025.05.012
文献标志码:
A
摘要:
目的:评价修和方加减联合紫杉醇(PTX)+铂类方案对手术切除气血两虚型卵巢癌(OC)患者近远期预后、中医证候和免疫功能的影响。方法:选取接受手术切除治疗的气血两虚型OC患者80例,根据术后治疗方案不同分为化疗组(PTX+铂类方案)和联合组(修和方加减联合PTX +铂类方案),各40例。观察并比较两组患者的近远期预后、中医证候改善情况以及免疫功能变化。结果:联合组客观有效率明显高于化疗组(77.50% 与52.50%,P<0.05),中位PFS和中位OS亦显著长于化疗组(P<0.05); 两组治疗后中医证候总积分均较治疗前明显减少(P<0.05),而联合组减少幅度更大(P<0.05); 联合组治疗后CD4+、CD4+/CD8+、NK细胞活性明显高于化疗组,CD8+显著低于化疗组(P<0.05); 联合组与化疗组在不良反应的分级中比较有统计学差异(P<0.05)。结论:修和方加减联合PTX +铂类方案能够显著提高手术切除OC(气血两虚证)患者的近远期疗效,改善中医证候,增强患者的免疫功能,用药具有一定安全性。
Abstract:
Objective:To evaluate the effects of modified Xiuhe Prescription combined with paclitaxel(PTX)and platinum on the short-term and long-term prognosis,traditional Chinese medicine syndromes,and immune function of patients with surgically resected ovarian cancer(OC)of qi and blood deficiency type.Methods:80 patients with qi and blood deficiency type OC who underwent surgical resection were selected and divided into a chemotherapy group(PTX+platinum)and a combination group(modified Xiuhe prescription combined with PTX+platinum)according to different postoperative treatment plans,with 40 patients in each group.Observe and compare the short-term and long-term prognosis,improvement of traditional Chinese medicine syndromes,and changes in immune function between two groups of patients.Results:The objective effective rate of the combination group was higher than that of the chemotherapy group(77.50% vs.52.50%,P<0.05),and the median PFS and median OS were also longer than those of the chemotherapy group(P<0.05).After treatment,the total score of traditional Chinese medicine syndrome in both groups decreased compared to before treatment(P<0.05),with a greater decrease in the combination group(P<0.05).After treatment,the CD4+,CD4+/CD8+,and NK cell activity in the combination group were significantly higher than those in the chemotherapy group,while CD8+was significantly lower than that in the chemotherapy group(P<0.05).The combination group and the chemotherapy group compared in the grade of myelosuppression,gastrointestinal reaction,neurological and hepatorenal toxicity(P<0.05).Conclusion:The combination of modified Xiuhe Prescription and PTX+platinum can significantly improve the short-and long-term efficacy of surgical resection of OC(Qi and Blood Deficiency Syndrome)patients,improve traditional Chinese medicine syndromes,enhance patients' immune function,and has certain safety.

参考文献/References:

[1] 许静,李霞.化瘀利水方联合腹腔热灌注化疗治疗原发性卵巢癌伴癌性腹水疗效观察[J].陕西中医,2023,44(9):1202-1204,1219.
[2] KONSTANTINOPOULOS P A,MATULONIS U A.Clinical and translational advances in ovarian cancer therapy[J].Nat Cancer,2023,4(9):1239-1257.
[3] 王静,张虹宇,张磊,等.动脉灌注化疗联合细胞因子诱导杀伤细胞治疗晚期卵巢癌疗效及对患者血清癌胚抗原、糖类抗原125、可溶性B7-H4蛋白水平的影响[J].陕西医学杂志,2024,53(2):199-202,206.
[4] 周诗杰,方珈文,姜雯.1990-2019年中国宫颈癌和卵巢癌疾病负担趋势及预测研究[J].中华肿瘤防治杂志,2024,31(11):662-669.
[5] LHEUREUX S,GOURLEY C,VERGOTE I,et al.Epithelial ovarian cancer[J].Lancet,2019,393(10177):1240-1253.
[6] 邵海鸥,李美,刘小红,等.修和方加减联合TC化疗对中晚期卵巢癌(气血亏虚证)的效果及作用探讨[J].四川中医,2023,41(4):152-155.
[7] 李小平,姜洁.妇科恶性肿瘤紫杉类药物临床应用专家共识[J].现代妇产科进展,2019,28(10):724-730.
[8] 刘少璇,李佳,刘芳媛,等.基于“亢害承制”理论辨析卵巢癌因机证治[J].陕西中医,2022,43(7):925-928..
[9] 李惠,陈俊,张娥.修和方加减联合TC化疗治疗中晚期卵巢癌临床研究[J].新中医,2023,55(9):165-169.
[10] SCHWARTZ L H,LITIERE S,DE VRIES E,et al.RECIST 1.1-Update and clarification:From the RECIST committee[J].Eur J Cancer,2016,62:132-137.
[11] TROTTI A,COLEVAS A D,SETSER A,et al.CTCAE v3.0:Development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
[12] 王静,张虹宇,张磊,等.长链非编码RNA PVT1调控表皮生长因子受体/有丝分裂原活性蛋白激酶通路对卵巢癌细胞的影响实验研究[J].陕西医学杂志,2024,53(11):1454-1458.
[13] 张婧.淋巴结切除在晚期卵巢癌手术治疗中的争议[J].实用妇产科杂志,2020,36(9):671-675.
[14] 李璡,温灏,刘淑娟,等.2023年中国卵巢癌诊疗现状白皮书[J].中国实用妇科与产科杂志,2023,39(12):1225-1232.
[15] 沈淑琴.甘麦大枣汤及归脾汤联合TC/TP对气血两虚证卵巢癌患者临床疗效、内分泌功能及骨髓抑制情况分析[J].时珍国医国药,2023,34(3):627-629.
[16] 刘芳媛,徐佳越,韩凤娟.桂枝茯苓丸治疗卵巢癌作用机制研究进展[J].中国实验方剂学杂志,2022,28(3):220-225.
[17] 张俐佳,刘业,孙姮,等.刘松江运用芪桂消癥方治疗卵巢癌经验[J].辽宁中医杂志,2021,48(10):21-24.
[18] 陈双凤,吉亚南.温阳活血方对卵巢癌患者免疫指标及炎性因子的影响[J].陕西中医,2021,42(10):1371-1374.
[19] 张强.扶正固肾汤对48例早中期卵巢癌患者术后化疗毒副作用及血清CA125、CA153、CEA水平的影响[J].福建中医药,2021,52(2):59-60.
[20] 王谦,薛晓鸥,祝洁,等.妇科恶性肿瘤手术、放化疗后患者证型分布的文献研究及系统评价[J].世界中西医结合杂志,2020,15(9):1619-1622,1629.
[21] 邵海鸥,李美,刘小红,等.修和方加减联合TC化疗对中晚期卵巢癌(气血亏虚证)的效果及作用探讨[J].四川中医,2023,41(4):152-155.
[22] MORAND S,DEVANABOYINA M,STAATS H,et al.Ovarian cancer immunotherapy and personalized medicine[J].Int J Mol Sci,2021,22(12):6532.
[23] 付鑫,吴茗,陈献,等.mTOR信号通路在调控卵巢癌CD4+ Treg糖代谢中的作用[J].南京医科大学学报(自然科学版),2023,43(5):604-610.
[24] 宗丽菊,向阳.上皮性卵巢癌的免疫治疗现状与问题[J].实用妇产科杂志,2020,36(2):93-95.
[25] 卢永红.卵巢癌患者组织及外周血CD8+T细胞中调节性T细胞相关分子标志物的表达及意义[J].实用癌症杂志,2019,34(8):1271-1274.

相似文献/References:

[1]常丰葛,张 珂,马玉瑶,等.白花蛇舌草提取物对卵巢癌模型大鼠的疗效及对其血清性激素水平的影响*[J].陕西中医,2019,(6):687.
　CHANG Fengge,ZHANG Ke,MA Yuyao,et al.Effect of hedyotis diffusa extract on ovarian cancer model rats and its effect on serum sex hormone levels[J].,2019,(5):687.
[2]王沈峰,金 迎,周禄荣,等.益气活血法治疗卵巢癌及对患者血清人附睾蛋白4、间皮素及肿瘤标记物的影响研究*[J].陕西中医,2020,(5):646.[doi:DOI:10.3969/j.issn.10007369.2020.05.026]
　WANG Shenfeng,JIN Ying,ZHOU Lurong,et al.Yiqi Huoxue method in the treatment of ovarian cancer and effects on serum HE4,SMRP and tumor markers[J].,2020,(5):646.[doi:DOI:10.3969/j.issn.10007369.2020.05.026]
[3]胡天祺,杨梦琪,杨 红,等.益气养阴方对卵巢癌术后患者化疗不良反应及生存质量的影响[J].陕西中医,2021,(4):434.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.007]
　HU Tianqi,YANG Mengqi,YANG Hong,et al.Effect of Yiqi Yangyin recipe on the adverse reaction effects and quality of life in patients with ovarian cancer undergoing chemotherapy[J].,2021,(5):434.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.007]
[4]李成斐,朱 萍,于 佳,等.益气活血解毒方联合化疗治疗晚期卵巢癌疗效及对患者免疫通路相关靶基因的影响[J].陕西中医,2021,(8):1072.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.021]
　LI Chengfei,ZHU Ping,YU Jia,et al.The effect of Yiqi Huoxie Jiedu decoction combined with TC regimen on advanced ovarian cancer and related target genes of immune pathway[J].,2021,(5):1072.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.021]
[5]王小玉,韩凤娟.基于“天癸-肾阳-命门”学说探究卵巢癌发病机制[J].陕西中医,2021,(9):1261.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.029]
[6]陈双凤,吉亚南.温阳活血方对卵巢癌患者免疫指标及炎性因子的影响[J].陕西中医,2021,(10):1371.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.011]
[7]刘少璇,李 佳,刘芳媛,等.基于“亢害承制”理论辨析卵巢癌因机证治[J].陕西中医,2022,(7):925.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.027]
　LIU Shaoxuan,LI Jia,LIU Fangyuan,et al.An analysis of mechanism in ovarian cancer based on the theory of “restraining excessiveness to acquire harmony”[J].,2022,(5):925.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.027]

备注/Memo

备注/Memo:
[基金项目]江苏省妇幼健康科研项目(F202014)
更新日期/Last Update: 2025-05-08